Propionyl-L-carnitine dilates human subcutaneous arteries through an endothelium-dependent mechanism

被引:43
作者
Cipolla, MJ
Nicoloff, A
Rebello, T
Amato, A
Porter, JM
机构
[1] Oregon Hlth Sci Univ, Div Vasc Surg, Dept Surg, Portland, OR 97201 USA
[2] Sigma Tau Pharmaceut, Gaithersburg, MD USA
关键词
D O I
10.1016/S0741-5214(99)70251-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: The vasoactive effects of propionyl-1-carnitine (PLC) on human arteries, including endothelial and smooth muscle cell influences, were studied. Methods: Small (less than 200 mu m) subcutaneous fat arteries (n = 19), obtained from human patients undergoing vascular surgery, were dissected and mounted in an arterio-graph system that allowed measurement of lumen diameter and control of transmural pressure. To investigate the role of the endothelium, arteries were compared intact, intact and in the presence of either 0.3 mmol/L nitro-1-arginine (an inhibitor of nitric oxide synthesis) or 10 mu mol/L indomethacin (an inhibitor of prostaglandin synthesis), or denuded of endothelium. After a 1-hour equilibration at a pressure of 50 mm Hg, arteries were precontracted 50% with an intermediate concentration of norepinephrine, and clinically relevant concentrations of PLC (0.1 to 100 mu mol/L) were cumulatively added to the bath while the lumen diameter was continually measured. Results: Intact arteries dose-dependently dilated to PLC, with the half maximal dilation occurring at 2.9 +/- 1.2 mu mol/L, increasing diameter 91% +/- 5% at 100 mu mol/L. In contrast, PLC had significantly less effect on deendothelialized arteries, increasing diameter only 24% +/- 11% at 100 mu mol/L (P < .01 vs. intact). This indicates the endothelial dependency of this compound. Blockade of nitric oxide did not inhibit this vasodilation, with the half-maximal response occurring at 8.6 +/- 7 mu mol/L, increasing diameter 85% +/- 8% at 100 mu mol/L (P > .05 vs, intact). However, this vasodilation was significantly diminished in the presence of indomethacin, which dilated arteries only 53% +/- 18% at 100 mu mol/L (P < .01 vs, intact; P > .05 vs. denuded). Conclusion: PLC is an endothelium-dependent vasodilator, the mechanism of which is partially mediated by prostaglandin synthesis, not nitric oxide. The beneficial effects of this compound may, in part, be related to vasodilation and enhanced blood flow.
引用
收藏
页码:1097 / 1103
页数:7
相关论文
共 25 条
[11]   THE EFFECT OF ACUTE FEEDING OF CARNITINE, ACETYL CARNITINE AND PROPIONYL CARNITINE ON BASAL AND A23187-STIMULATED EICOSANOID RELEASE FROM RAT CARRAGEENAN-ELICITED PERITONEAL-MACROPHAGES [J].
ELLIOTT, GR ;
LAUWEN, APM ;
BONTA, IL .
BRITISH JOURNAL OF NUTRITION, 1990, 64 (02) :497-503
[12]   SITES OF ACTION OF CARNITINE AND ITS DERIVATIVES ON THE CARDIOVASCULAR-SYSTEM - INTERACTIONS WITH MEMBRANES [J].
FRITZ, IB ;
ARRIGONIMARTELLI, E .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (10) :355-360
[13]   MECHANICAL-BEHAVIOR OF PRESSURIZED INVITRO PREARTERIOLAR VESSELS DETERMINED WITH A VIDEO SYSTEM [J].
HALPERN, W ;
OSOL, G ;
COY, GS .
ANNALS OF BIOMEDICAL ENGINEERING, 1984, 12 (05) :463-479
[14]   CARNITINE AND ACYLCARNITINE METABOLISM DURING EXERCISE IN HUMANS - DEPENDENCE ON SKELETAL-MUSCLE METABOLIC STATE [J].
HIATT, WR ;
REGENSTEINER, JG ;
WOLFEL, EE ;
RUFF, L ;
BRASS, EP .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1167-1173
[15]   ASPECTS OF FATTY-ACID METABOLISM IN VASCULAR ENDOTHELIAL-CELLS [J].
HULSMANN, WC ;
DUBELAAR, ML .
BIOCHIMIE, 1988, 70 (05) :681-686
[16]   PALMITOYL-L-CARNITINE MODIFIES THE FUNCTION OF VASCULAR ENDOTHELIUM [J].
INOUE, N ;
HIRATA, K ;
AKITA, H ;
YOKOYAMA, M .
CARDIOVASCULAR RESEARCH, 1994, 28 (01) :129-134
[17]  
KOSOLCHAROEN P, 1981, CURR THER RES CLIN E, V30, P753
[18]  
OSOL G, 1989, BLOOD VESSELS, V26, P320
[19]   L-PROPIONYLCARNITINE INCREASES POSTISCHEMIC BLOOD-FLOW BUT DOES NOT AFFECT RECOVERY OF ENERGY-CHARGE [J].
SASSEN, LMA ;
BEZSTAROSTI, K ;
VANDERGIESSEN, WJ ;
LAMERS, JMJ ;
VERDOUW, PD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 261 (01) :H172-H180
[20]   PROPIONYL-L-CARNITINE - BIOCHEMICAL SIGNIFICANCE AND POSSIBLE ROLE IN CARDIAC METABOLISM [J].
SILIPRANDI, N ;
DILISA, F ;
MENABO, R .
CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 :11-16